Karyopharm Therapeutics
KPTI
KPTI
119 hedge funds and large institutions have $738M invested in Karyopharm Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
119
Holders Change
+11
Holders Change %
+10.19%
% of All Funds
2.72%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
17
Increased
34
Reduced
37
Closed
6
Calls
$1.14M
Puts
$3.56M
Net Calls
-$2.42M
Net Calls Change
-$2.46M
Top Buyers
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.1M |
| 2 |
DM
Deerfield Management
New York
|
+$8.09M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5M |
| 4 |
BlackRock
New York
|
+$3.49M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$2.89M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.76M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.15M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.48M |
| 5 |
Goldman Sachs
New York
|
-$3.9M |
